Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...
Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...
Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback